Available Clinical Trials

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355). E-mail: askroswell@roswellpark.org
 

A phase 1b dose optimization study of sovilnesib (an oral KIF18A inhibitor) in subjects with advanced high grade serous ovarian cancer

Principal Investigator: McLean, Karen

NRG-GY019 A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Principal Investigator: Zsiros, Emese

A COMBOMATCH TREATMENT TRIAL: PALBOCICLIB AND BINIMETINIB IN RAS-MUTANT CANCERS NCI-supplied agent(s): Palbociclib (NSC #772256); Binimetinib (NSC #788187)

Principal Investigator: Levine, Ellis G

(EAY191-N4): A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers (ComboMATCH Treatment Trial)

Principal Investigator: Levine, Ellis G

Randomized Phase 2 Trial of APL-2 with Pembrolizumab vs. APL-2 with Pembrolizumab and Bevacizumab vs. Bevacizumab alone in Patients with Recurrent Ovarian Cancer and Persistent Malignant Effusion

Principal Investigator: Zsiros, Emese